Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy

Pediatr Blood Cancer. 2022 Nov;69(11):e29742. doi: 10.1002/pbc.29742. Epub 2022 Jun 2.

Authors

Gauthier Toutain¹, Victoria Min¹, Angélique Rome¹, Nicolas Andre^{1

2

3}

Affiliations

¹ Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France.
² Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), CLIPP2, APHM, Marseille, France.
³ SMARTc Unit, CRCM Inserm 1068-CNRS UMR 7258 Aix-Marseille University, Marseille, France.

PMID: 35652680
DOI: 10.1002/pbc.29742

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Liquid Biopsy
Mutation
Mutation, Missense
Neuroblastoma* / drug therapy
Neuroblastoma* / genetics
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf* / genetics
Pyridones / therapeutic use
Pyrimidinones

Substances

Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf